ORYZON’s iadademstat shows efficacy signs in relapsed SCLC
MADRID, SPAIN and CAMBRIDGE MA.
• Preliminary data from CLEPSIDRA Phase II trial presented at WCLC 2019
• Case study showing a 86% tumor reduction
• Additional data will be presented late September at ESMO-2019
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today presents the first preliminary data from CLEPSIDRA, a Phase II trial investigating iadademstat in combination with standard-of-care in relapsing small cell lung cancer (SCLC) patients.